Generate Biomedicines, Inc. (GENB)
Generate Biomedicines will go public soon. The estimated IPO date is February 27, 2026.
IPO Price Range
$15.00 - $17.00
Shares Offered
25,000,000
Deal Size
$400.00M
Generate Biomedicines Revenue
In the year 2025, Generate Biomedicines had annual revenue of $31.89M with 55.89% growth.
Revenue (ttm)
$31.89M
Revenue Growth
+55.89%
P/S Ratio
63.94
Revenue / Employee
$102,221
Employees
312
Market Cap
2.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.89M | 11.43M | 55.89% |
| Dec 31, 2024 | 20.46M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGENB News
- 8 hours ago - Drug developer Generate Biomedicines raises $400 million in US IPO - Reuters
- 9 hours ago - Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering - PRNewsWire
- 3 days ago - Generate Biomedicines aims to raise $425 million in US IPO - Reuters
- 6 days ago - U.S. IPO Weekly Recap: IPO Market Stays Fairly Quiet During The Short Holiday Week - Seeking Alpha
- 20 days ago - U.S. IPO Weekly Recap: 7 IPOs Make It One Of The Busiest Weeks In 4 Years - Seeking Alpha
- 20 days ago - Generate Biomedicines Begins IPO Push With Major Collaboration Deals - Seeking Alpha
- 22 days ago - Generate Biomedicines, Clinical-Stage Generative Biology Company Designing AI-Engineered Protein Therapeutics, Files for Nasdaq IPO - TradingView News
- 22 days ago - Generate Biomedicines IPO Registration Document (S-1) - SEC